Business and News Update - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Business and News Update Industry news focusing on the people and organizations who work in the clinical trials profession.

Source: Applied Clinical Trials


People


Linda Deal
  • ERT (Philadelphia, PA) has appointed Linda Deal to lead ERT's Health Outcomes Research initiatives.
  • inVentiv Health (Burlington, MA) has appointed Mark Dmytruk as President of inVentiv Health Patient Outcomes.
  • With more than 20 years experience in the laboratory manufacturing and distribution services, construction, and public accounting industries, Christopher O'Connell has joined Marken (London, UK) as the company's Chief Financial Officer. Marken has also appointed Frank J. Wright as the Interim President of the Clinical Trials Distribution Business Unit.
  • BioConvergence (Bloomington, IN) has appointed Kathy Eddy as its Chief Financial Officer, where she will oversee the finance, human resources, and information technology departments.
  • The CRS Group (Andernach , Germany) has been joined by two recent arrivals. Berthold Lausecker, PhD, became CRS's new Director of Bioanalytics this Spring and Wolfgang Höffer, MD, joined as Director, Corporate Development.


Mark Dmytruk
Alliances
  • Worldwide Clinical Trials (King of Prussia, PA) and Thomas Jefferson University's School of Population (Philadelphia, PA) have entered into an alliance to provide pharmaceutical and biotechnology clients with a broad range of outcomes research services including comparative effectiveness, burden of illness, and quality of life studies.
  • INC Research (Raleigh, NC) and Debiopharm Group (Lausanne, Switzerland) announced a strategic partnership where Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm's pipeline.
  • Medidata Solutions (New York, NY) announced that specialty contract research organization QCTR (Stirling, UK) has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.


ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here